

Expression of E-cadherin in gastric carcinoma and its correlation with lymph node micrometastasis

Ze-Yu Wu, Wen-Hua Zhan, Jing-Hua Li, Yu-Long He, Jian-Ping Wang, Ping Lan, Jun-Sheng Peng, Shi-Rong Cai

Ze-Yu Wu, Wen-Hua Zhan, Yu-Long He, Jian-Ping Wang, Ping Lan, Jun-Sheng Peng, Shi-Rong Cai, Department of Gastrointestinal and Pancreatic Surgery, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China

Jing-Hua Li, Department of Parasitology, Zhong Shan Medical College, Sun Yat-Sen University, Guangzhou 510089, Guangdong Province, China

Supported by the National Natural Science Foundation of China, No. 30271276

Correspondence to: Dr. Wen-Hua Zhan, Department of Gastrointestinal and Pancreatic Surgery, the First Affiliated Hospital, Sun Yat-Sen University, Guangzhou 510080, Guangdong Province, China. wenhuazh@21cn.com

Telephone: +86-20-87755766-8211 Fax: +86-20-87335945

Received: 2004-07-28 Accepted: 2004-09-30

classification and depth of tumor invasion are significantly associated with lymph node micrometastases. Our findings also indicate that E-cadherin may play an important role in determining the growth type and differentiation of gastric carcinoma. The loss of E-cadherin expression may contribute to LNM.

© 2005 The WJG Press and Elsevier Inc. All rights reserved.

Key words: Gastric carcinoma; Lymph node micrometastasis; Cytokeratin-20; E-cadherin; Reverse transcription polymerase chain reaction; Immunohistochemistry

Wu ZY, Zhan WH, Li JH, He YL, Wang JP, Lan P, Peng JS, Cai SR. Expression of E-cadherin in gastric carcinoma and its correlation with lymph node micrometastasis. *World J Gastroenterol* 2005; 11(20): 3139-3143

<http://www.wjgnet.com/1007-9327/11/3139.asp>

Abstract

AIM: To examine the expression of E-cadherin in the primary tumor and to evaluate its relationship with lymph node micrometastasis (LNM).

METHODS: The authors studied 850 lymph nodes resected from 30 patients with gastric carcinoma who underwent gastrectomy with lymphadenectomy using reverse transcription polymerase chain reaction (RT-PCR) assay in addition to H&E staining. Cytokeratin-20 (CK-20) gene marker was used in this assay. The level of E-cadherin expression in the primary tumor was examined by immunochemical technique (EliVision™ plus).

RESULTS: LNM was detected in 77 (12.5%) lymph nodes of 14 patients (46.7%) with gastric carcinoma. The incidence of LNM was significantly higher in the diffuse type (12 of 19 cases, 63.2%) than in the intestinal type of gastric carcinoma (2 of 11 cases, 18.2%, $P = 0.026$). The incidence of LNM also increased in accordance with the depth of tumor invasion. The loss of expression of E-cadherin in primary tumors was found in 14 (46.7) of 30 tumors. The absence of E-cadherin expression was significantly associated with the Lauren classification ($P = 0.026$), lymph node metastasis ($P = 0.011$), the grade of differentiation ($P = 0.004$) and the lymphatic invasion ($P = 0.001$). Expression of E-cadherin was negative in 10 (71.4%) of the 14 patients with LNM, and in 4 (25%) of the 16 patients without LNM ($P = 0.026$).

CONCLUSION: The current results indicate that the RT-PCR assay is useful for the detection of LNM and can significantly increase the detection rate of lymph node metastasis in patients with gastric carcinoma. The Lauren

INTRODUCTION

Lymph node metastasis is one of the most important prognostic factors in gastric carcinoma^[1-3]. Histopathological examination of resected lymph nodes using H&E staining has been the gold standard for diagnosis of lymph node metastasis; however, the incidence of LNM is often overlooked by the routine histologic method. Recent advances in immunohistochemical and molecular biologic techniques have made it possible to detect LNM not evidenced by routine H&E evaluation. Cytokeratin is a component of the cytoskeleton of epithelial cells that is not present in normal lymph nodes^[4]. Several investigators have reported that cytokeratin immunostaining can identify lymph node micrometastases missed by routine H&E staining in patients with gastric carcinoma^[5-7]. However, it has been reported that the immunohistochemical technique might still generate false-negative results from overlooking possible micrometastases localized outside the cutting slice or false-positive results due to antibody cross-reactivity with host stromal or inflammatory cells^[8]. In the current study, to overcome these problems, we applied RT-PCR assay to detect micrometastasis in the lymph nodes resected from 30 cases of stage I-IV gastric carcinomas, and examined the relationship between LNM and clinicopathologic characteristics. Moreover, the mechanism of LNM is still not completely known presently. E-cadherin is an adhesive molecule of epithelial cells and plays an important role in the formation and maintenance of epithelia architecture. It has been reported that reduced expression of E-cadherin is

of E-cadherin in the primary tumor was graded according to the proportion of positive tumor cells. If more than 25% of the tumor cells were positively stained for E-cadherin, the tumor was classified as having preserved E-cadherin expression. In contrast, if 25% or less of the tumor cells were positively stained, the tumor was classified as having the loss of E-cadherin expression. The stained slides were observed independently by two pathologists who had no knowledge of the clinicopathological data. All the staining results for E-cadherin were examined in relation to the clinicopathological parameters of the tumors.

Statistical analysis

Statistical analysis was performed by Fisher's exact test to examine the association of LNM and the expression of E-cadherin in the primary tumor with the clinicopathologic characteristics of the primary tumor, and examine the relationship between the expression of E-cadherin in the primary tumor and LNM. Statistical significance was defined as $P < 0.05$.

RESULTS

Correlation between LNM and clinicopathologic characteristics

Routine examination by H&E staining confirmed metastasis in 233 lymph nodes from 20 patients. All these 233 lymph nodes were cytokeratin-20 positive; moreover, LNM was detected in an additional 67 lymph nodes in 12 cases of these 20 patients. LNM was also detected in 10 lymph nodes from two cases of 10 patients who had no obvious metastases identified by H&E staining. Totally, LNM was identified only by the RT-PCR assay in 77 (12.5%) lymph nodes of 14 patients (46.7%) with gastric carcinoma. From Table 1, we also found that the incidence of LNM was

Table 1 Correlation between LNM and clinicopathologic characteristics

Variable	Patients (n)	LNM		P
		Negative (%)	Positive (%)	
Gender				
Male	17	9 (52.9)	8 (47.1)	P = 1.000
Female	13	7 (53.8)	6 (46.2)	
Age				
<50 yr	10	4 (40)	6 (60)	P = 0.442
≥R50 yr	20	12 (60)	8 (40)	
Superficial diameter				
<5 cm	17	9 (52.9)	8 (47.1)	P = 1.000
≥R5 cm	13	7 (53.8)	6 (46.2)	
Tumor location				
Upper/middle third	17	8 (47.1)	9 (52.9)	P = 0.484
Lower third	13	8 (61.5)	5 (38.5)	
Histologic type				
Intestinal	11	9 (81.8)	2 (18.2)	P = 0.026
Diffuse	19	7 (36.8)	12 (63.2)	
Depth of invasion				
T1/T2	21	14 (66.7)	7 (33.3)	P = 0.046
T3/T4	9	2 (22.2)	7 (77.8)	
Histologic differentiation				
Well/moderate	13	9 (69.2)	4 (30.8)	P = 0.159
Poor	17	7 (58.8)	10 (41.2)	
Lymphatic invasion				
Positive	18	7 (38.9)	11 (61.1)	P = 0.072
Negative	12	9 (75)	3 (25)	
Vascular invasion				
Positive	5	3 (60)	2 (40)	P = 1.000
Negative	25	13 (52)	12 (48)	

significantly higher in the diffuse type (12 of 19 cases, 63.2%) than in the intestinal type of gastric carcinoma (2 of 11 cases, 18.2%, $P = 0.026$). Micrometastases increased in accordance with the depth of tumor invasion. Seven of 21 cases that had lesions within submucosa layer were detected to have micrometastases in the lymph nodes; in contrast, seven of nine cases with invasion reaching the muscularis propria and deeper invasion had micrometastases ($P = 0.046$). Other clinicopathologic findings including gender, age, location, diameter, histologic differentiation, lymphatic invasion and vascular invasion had no statistically significant correlation with the incidence of LNM ($P > 0.05$).

Expression of E-cadherin

The loss of expression of E-cadherin in primary tumors was found in 14 (46.7) of 30 tumors. From Table 2, we found that the absence of E-cadherin expression was significantly associated with The Lauren classification ($P = 0.026$), lymph node metastasis ($P = 0.011$), the grade of differentiation ($P = 0.004$) and the lymphatic invasion ($P = 0.001$), but not correlated with age, gender, location, diameter and depth of tumor invasion ($P > 0.05$).

Table 2 Correlation between the expression of E-cadherin in primary tumors and clinicopathologic characteristics

Variable	Patients (n)	Expression of E-cadherin		P
		Negative (%)	Positive (%)	
Gender				
Male	17	7 (41.2)	10 (58.8)	P = 0.713
Female	13	7 (53.8)	6 (46.2)	
Age				
<50 yr	10	3 (30)	7 (70)	P = 0.260
≥R50 yr	20	11 (55)	9 (45)	
Superficial diameter				
<5 cm	17	7 (41.2)	10 (58.8)	P = 0.713
≥R5 cm	13	7 (53.8)	6 (46.2)	
Tumor location				
Upper/middle third	17	8 (47.1)	9 (52.9)	P = 1.000
Lower third	13	6 (46.2)	7 (53.8)	
Histologic type				
Intestinal	11	2 (18.2)	9 (81.8)	P = 0.026
Diffuse	19	12 (63.2)	7 (36.8)	
Depth of invasion				
T1/T2	21	8 (38.1)	13 (61.9)	P = 0.236
T3/T4	9	6 (66.7)	3 (33.3)	
Histologic differentiation				
Well/moderate	13	2 (15.4)	11 (84.6)	P = 0.004
Poor	17	12 (70.6)	5 (29.4)	
Lymph node metastasis				
Positive	18	12 (66.7)	6 (33.3)	P = 0.011
Negative	12	2 (16.7)	10 (83.3)	
Lymphatic invasion				
Positive	18	13 (72.2)	5 (27.8)	P = 0.001
Negative	12	1 (8.3)	11 (91.7)	

Correlation between LNM and the expression of E-cadherin

From Table 3, we found that expression of E-cadherin was negative in 10 (71.4%) of the 14 patients with LNM, and in 4 (25%) of the 16 patients without LNM. The difference between these two groups was statistically significant ($P = 0.026$).

Table 3 Correlation between LNM and the expression of E-cadherin

LNM	Patients (n)	Expression of E-cadherin		P
		Negative (%)	Positive (%)	
Positive	14	10 (71.4)	4 (28.6)	P = 0.026
Negative	16	4 (25)	12 (75)	

DISCUSSION

It is well known that lymph node metastasis is the most important prognostic factor for patients with gastric carcinoma. However, even after undergoing radical resection of primary tumors and lymph nodes, about 20% of patients with gastric carcinoma reportedly die of recurrence^[13], and about 3% of patients with early-stage gastric carcinoma also reportedly die of recurrence^[14]. These findings suggest the existence of LNM that cannot be identified by routine H&E staining. Several investigators have demonstrated the usefulness of immunohistochemical technique for detection of micrometastases in lymph nodes of gastric carcinoma patients^[5-7,15,16]. In the present study, RT-PCR assay was applied to detect micrometastasis in the lymph nodes resected from 30 cases of stage I-IV gastric carcinomas. Totally, LNM was detected by the RT-PCR assay in 77 (12.5%) lymph nodes of 14 patients (46.7%) with gastric carcinoma. The incidence of LNM was significantly higher in the diffuse type (12 of 19 cases, 63.2%) than in the intestinal type of gastric carcinoma (2 of 11 cases, 18.2%, $P = 0.026$). Similar to our results, Ishida *et al*, studied 2 446 lymph nodes removed during surgery for 109 cases of gastric carcinoma, including Stages I-IV. Metastases were confirmed in 230 lymph nodes (9.4%) stained with H&E, and an additional 201 lymph nodes (17.6%) had micrometastases identified only by immunostaining. They also demonstrated that the diffuse type had more micrometastases than the intestinal type^[5].

In addition, we also found that there was a significant correlation between LNM and depth of tumor invasion. Seven of 21 cases that had lesions within submucosa layer were detected to have micrometastases in the lymph nodes; in contrast, seven of nine cases with invasion reaching the muscularis propria and deeper invasion had micrometastases ($P = 0.046$). Micrometastases increased in accordance with the depth of tumor invasion. Tsujitani *et al*, obtained almost the same results as ours. They reported that micrometastases in the lymph nodes were found in 18% of mucosal cancer, 25% of submucosal cancer, and 65% of T3 (serosal) cancer specimens, with cancer-free nodes examined by H&E staining^[17].

These results indicate that RT-PCR assay is clearly more sensitive than routine histopathological examination for detection of micrometastases in lymph nodes of gastric carcinoma patients. Lymph node micrometastases are significantly associated with the Lauren classification and depth of tumor invasion.

E-cadherin is a 120-ku transmembrane glycoprotein that is responsible for calcium-dependent intercellular adhesion by homotypic interactions. E-cadherin plays an important role in maintaining cell polarity and tissue morphology^[18]. Previous studies showed that 43.5-72% of gastric carcinoma

had reduction or loss of E-cadherin expression^[19,20]. In our study, the loss of E-cadherin expression was observed in 46.7% (14 of 30 cases) of gastric carcinoma. We also found the absence of E-cadherin expression was significantly related with the histologic type and the grade of tumor differentiation. In 19 gastric carcinomas with diffuse type of growth 12 showed negative E-cadherin expression, while in 11 gastric carcinomas with intestinal type of growth only two showed negative E-cadherin expression. The difference was statistically significant ($P = 0.026$). In 17 poorly-differentiated gastric carcinomas 12 showed negative E-cadherin expression, while in 13 well- or moderately-differentiated gastric carcinomas only two showed negative E-cadherin expression. The difference was also statistically significant ($P = 0.004$). Recently, several scholars also reported that the reduction or absence of E-cadherin expression occurred more frequently in diffuse than intestinal type of gastric carcinoma, and correlated with poor differentiation^[21,22]. These findings indicate that E-cadherin may play an important role in determining the growth type and differentiation of gastric carcinoma.

The E-cadherin gene has generally been recognized as an invasion-suppressor gene^[23,24]. Chen *et al*^[22], reported that the loss of E-cadherin expression was significantly associated with tumor invasion. Yonemura *et al*^[20], also reported that reduced E-cadherin expression showed a strong relationship with positive serosal involvement and infiltrating type. In the present study, the absence of E-cadherin expression was more frequent in T3 or T4 tumors (six of nine tumors, 66.7%), compared with T1 or T2 tumors (8 of 21 tumors, 38.1%), but this difference was not statistically significant ($P = 0.236$). This may be explained by the fact that the cases in our study were comparatively few. To draw a further conclusion, larger sample investigations on gastric carcinoma are needed.

It has been reported that reduced expression of E-cadherin plays an important role in the development of lymph node metastases in patients with gastric carcinoma. However, the relationship between E-cadherin expression in the primary tumor and LNM has not been extensively discussed. In our study, we found that expression of E-cadherin was negative in 10 (71.4%) of the 14 patients with LNM, and in 4 (25%) of the 16 patients without LNM. The difference between these two groups was statistically significant ($P = 0.026$). The result indicates the loss of E-cadherin expression may contribute to LNM.

REFERENCES

- 1 Maruyama K, Gunven P, Okabayashi K, Sasako M, Kinoshita T. Lymph node metastases of gastric cancer. General pattern in 1931 patients. *Ann Surg* 1989; **210**: 596-602
- 2 Roder JD, Bottcher K, Siewert JR, Busch R, Hermanek P, Meyer HJ. Prognostic factors in gastric carcinoma. Results of the German Gastric Carcinoma Study 1992. *Cancer* 1993; **72**: 2089-2097
- 3 Shen KH, Wu CW, Lo SS, Hsieh MC, Hsia CY, Chiang SC, Lui WY. Factors correlated with number of metastatic lymph nodes in gastric cancer. *Am J Gastroenterol* 1999; **94**: 104-108
- 4 Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. *Cell* 1982; **31**: 11-24
- 5 Ishida K, Katsuyama T, Sugiyama A, Kawasaki S. Immu-

- nohistochemical evaluation of lymph node micrometastases from gastric carcinomas. *Cancer* 1997; **79**: 1069-1076
- 6 **Cai J**, Ikeguchi M, Maeta M, Kaibara N. Micrometastasis in lymph nodes and microinvasion of the muscularis propria in primary lesions of submucosal gastric cancer. *Surgery* 2000; **127**: 32-39
 - 7 **Fukagawa T**, Sasako M, Mann GB, Sano T, Katai H, Maruyama K, Nakanishi Y, Shimoda T. Immunohistochemically detected micrometastases of the lymph nodes in patients with gastric carcinoma. *Cancer* 2001; **92**: 753-760
 - 8 **Xu X**, Roberts SA, Pasha TL, Zhang PJ. Undesirable cytokeratin immunoreactivity of native nonepithelial cells in sentinel lymph nodes from patients with breast carcinoma. *Arch Pathol Lab Med* 2000; **124**: 1310-1313
 - 9 **Mayer B**, Johnson JP, Leidl F, Jauch KW, Heiss MM, Schildberg FW, Birchmeier W, Funke I. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. *Cancer Res* 1993; **53**: 1690-1695
 - 10 **Kinsella AR**, Green B, Lepts GC, Hill CL, Bowie G, Taylor BA. The role of the cell-cell adhesion molecule E-cadherin in large bowel tumour cell invasion and metastasis. *Br J Cancer* 1993; **67**: 904-909
 - 11 **Lauren P**. The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. An attempt at a histo-clinical classification. *Acta Pathol Microbiol Scand* 1965; **64**: 31-49
 - 12 **Okada Y**, Fujiwara Y, Yamamoto H, Sugita Y, Yasuda T, Doki Y, Tamura S, Yano M, Shiozaki H, Matsuura N, Monden M. Genetic detection of lymph node micrometastases in patients with gastric carcinoma by multiple-marker reverse transcriptase-polymerase chain reaction assay. *Cancer* 2001; **92**: 2056-2064
 - 13 **Tsushima K**, Sakata Y. Treatment of recurrent gastric cancer. *Gan To Kagaku Ryoho* 1998; **25**: 321-326
 - 14 **Ohgaki M**, Toshio T, Akeo H, Yamasaki J, Togawa T. Effect of extensive lymph node dissection on the survival of early gastric cancer. *Hepatogastroenterology* 1999; **46**: 2096-2099
 - 15 **Lee E**, Chae Y, Kim I, Choi J, Yeom B, Leong AS. Prognostic relevance of immunohistochemically detected lymph node micrometastasis in patients with gastric carcinoma. *Cancer* 2002; **94**: 2867-2873
 - 16 **Choi HJ**, Kim YK, Kim YH, Kim SS, Hong SH. Occurrence and prognostic implications of micrometastases in lymph nodes from patients with submucosal gastric carcinoma. *Ann Surg Oncol* 2002; **9**: 13-19
 - 17 **Tsujitani S**, Kaibara N. Clinical significance of molecular biological detection of micrometastases in gastric carcinoma. *Nihon Geka Gakkai Zasshi* 2001; **102**: 741-744
 - 18 **Takeichi M**. Cadherin cell adhesion receptors as a morphogenetic regulator. *Science* 1991; **251**: 1451-1455
 - 19 **Joo YE**, Rew JS, Choi SK, Bom HS, Park CS, Kim SJ. Expression of e-cadherin and catenins in early gastric cancer. *J Clin Gastroenterol* 2002; **35**: 35-42
 - 20 **Yonemura Y**, Endou Y, Kimura K, Fushida S, Bandou E, Taniguchi K, Kinoshita K, Ninomiya I, Sugiyama K, Heizmann CW, Schafer BW, Sasaki T. Inverse expression of S100A4 and E-cadherin is associated with metastatic potential in gastric cancer. *Clin Cancer Res* 2000; **6**: 4234-4242
 - 21 **Joo YE**, Rew JS, Kim HS, Choi SH, Park CS, Kim SJ. Changes in the E-cadherin-catenin complex expression in early and advanced gastric cancers. *Digestion* 2001; **64**: 111-119
 - 22 **Chen HC**, Chu RY, Hsu PN, Hsu PI, Lu JY, Lai KH, Tseng HH, Chou NH, Huang MS, Tseng CJ, Hsiao M. Loss of E-cadherin expression correlates with poor differentiation and invasion into adjacent organs in gastric adenocarcinomas. *Cancer Lett* 2003; **201**: 97-106
 - 23 **Mareel M**, Vleminckx K, Vermeulen S, Yan G, Bracke M, van Roy F. Downregulation *in vivo* of the invasion-suppressor molecule E-cadherin in experimental and clinical cancer. *Progress Takamatsu Symp* 1994; **24**: 63-80
 - 24 **Yonemura Y**, Ninomiya I, Kaji M, Sugiyama K, Fujimura T, Tsuchihara K, Kawamura T, Miyazaki I, Endou Y, Tanaka M. Decreased E-cadherin expression correlates with poor survival in patients with gastric cancer. *Anal Cell Pathol* 1995; **8**: 177-190